JavaScript is disabled in your browser. Please enable JavaScript to view this website.
AB265148

Human IER2 knockout HeLa cell line

Be the first to review this product! Submit a review

|

(0 Publication)

IER2 KO cell line available to order. KO validated by. Free of charge wild type control provided. Knockout achieved by using CRISPR/Cas9, 1 bp deletion in exon 2 and 1 bp insertion in exon 2.

View Alternative Names

ChxI protein homolog, ETR101, IER2_HUMAN, Immediate early protein, Immediate early response 2, Immediate early response gene 2 protein, MGC111472, MGC15265, Pip92, Protein ETR101, T lymphocyte activated protein

2 Images
Sanger Sequencing - Human IER2 knockout HeLa cell line (AB265148)
  • Sanger seq

Unknown

Sanger Sequencing - Human IER2 knockout HeLa cell line (AB265148)

Allele-2 : 1 bp insertion in exon 2.

Sanger Sequencing - Human IER2 knockout HeLa cell line (AB265148)
  • Sanger seq

Unknown

Sanger Sequencing - Human IER2 knockout HeLa cell line (AB265148)

Allele-1 : 1 bp deletion in exon 2.

Key facts

Cell type

HeLa

Species or organism

Human

Tissue

Cervix

Form

Liquid

form

Knockout validation

Sanger Sequencing

Mutation description

Knockout achieved by using CRISPR/Cas9, 1 bp deletion in exon 2 and 1 bp insertion in exon 2

Disease

Adenocarcinoma

Product details

Recommended control: Human wild-type HeLa cell line (ab255928). Please note a wild-type cell line is not automatically included with a knockout cell line order, if required please add recommended wild-type cell line at no additional cost using the code WILDTYPE-TMTK1.

We will provide viable cells that proliferate on revival.

This product is subject to limited use licenses from The Broad Institute, ERS Genomics Limited and Sigma-Aldrich Co. LLC, and is developed with patented technology. For full details of the licenses and patents please refer to our limited use license and patent pages.

What's included?

{ "values": { "1000000Cellsvial": { "sellingSize": "1000000 Cells/vial", "publicAssetCode":"ab265148-1000000Cells_vial", "assetComponentDetails": [ { "size":"1 x 1000000 Cells/vial", "name":"ab265148 Human IER2 knockout HeLa cell line", "number":"AB265148-CMP01" } ] }, "1000000Cellsvial": { "sellingSize": "1000000 Cells/vial", "publicAssetCode":"ab265148-1000000Cells_vial", "assetComponentDetails": [ { "size":"1 x 1000000 Cells/vial", "name":"ab265148 Human IER2 knockout HeLa cell line", "number":"AB265148-CMP01", "productcode":"" } ] } } }

Properties and storage information

Gene name
IER2
Gene editing type
Knockout
Gene editing method
CRISPR technology
Knockout validation
Sanger Sequencing
Shipped at conditions
Dry Ice
Appropriate short-term storage conditions
-196°C
Appropriate long-term storage conditions
-196°C

Handling procedures

Initial handling guidelines

Upon arrival, the vial should be stored in liquid nitrogen vapor phase and not at -80°C. Storage at -80°C may result in loss of viability.

1. Thaw the vial in 37°C water bath for approximately 1-2 minutes.
2. Transfer the cell suspension (0.8 mL) to a 15 mL/50 mL conical sterile polypropylene centrifuge tube containing 8.4 mL pre-warmed culture medium, wash vial with an additional 0.8 mL culture medium (total volume 10 mL) to collect remaining cells, and centrifuge at 201 x g (rcf) for 5 minutes at room temperature. 10 mL represents minimum recommended dilution. 20 mL represents maximum recommended dilution.
3. Resuspend the cell pellet in 5 mL pre-warmed culture medium and count using a haemocytometer or alternative cell counting method seed all remaining cells into a T25.
4. Incubate the culture at 37°C incubator with 5% CO2. Check the culture one day after revival and continue to check until 80% confluent. Media change can be given if needed.
5. Once confluent passage into an appropriate flask at a density of 2x104 cells/cm2. Seeding density is given as a guide only and should be scaled to align with individual lab schedules. Cultures should be monitored daily.

Subculture guidelines
  • All seeding densities should be based on cell counts gained by established methods.
  • A guide seeding density of 2x104 cells/cm2 is recommended.
  • Cells should be passaged when they have achieved 80-90% confluence.
Culture medium

DMEM (High Glucose) + 10% FBS

Cryopreservation medium

Cell Freezing Medium-DMSO Serum free media, contains 8.7% DMSO in MEM supplemented with methyl cellulose.

Supplementary information

This supplementary information is collated from multiple sources and compiled automatically.

The immediate early response gene 2 (IER2) also known as ETR101 is a protein with a molecular mass of approximately 30 kDa. Researchers often find IER2 expressed across various tissues including the heart kidney and brain. Being an immediate early gene IER2 rapidly responds to growth factors stress and other stimuli. Its function does not require de novo protein synthesis allowing an immediate response to environmental cues or cellular states.
Biological function summary

IER2 influences cell proliferation and differentiation. It interacts with several signaling pathways indicating its role in controlling cell cycle progression. Scientists have discussed IER2's involvement in cellular stress responses acting independently rather than as part of a larger protein complex. These activities help the protein regulate gene expression temporarily an important element in maintaining cellular homeostasis.

Pathways

IER2 functions within signaling networks essential for mitogenic responses and stress-activated MAPK pathways. It shares pathways with proteins such as c-Fos and c-Jun which are part of the AP-1 transcription factor complex. These connections position IER2 as a participant in pathways that manage cellular responses to external stimuli and internal signals important for cell growth and survival.

Scientists associate IER2 with cancer and neurodegenerative conditions. In cancer IER2 promotes metastasis by influencing cell migration and invasion often through interaction with matrix metalloproteinases. Additionally its dysregulation may contribute to neurodegenerative disorders linking it to proteins involved in neuronal survival and death. Understanding these interactions could provide insight into therapeutic targets for combatting related diseases.

Quality control

STR analysis

CSF1PO, D13S317, D7S820, D5S818, TH01, D16S539, TPOX

Cell culture

Biosafety level

EU: 2 US: 2

Adherent/suspension

Adherent

Gender

Female

Product protocols

Product promise

We are committed to supporting your work with high-quality reagents, and we're here for you every step of the way. In the unlikely event that one of our products does not perform as expected, you're protected by our Product Promise.
For full details, please see our Terms & Conditions

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.

For licensing inquiries, please contact partnerships@abcam.com